Condition: Cerebral Adrenoleukodystrophy (cALD) · Sponsor: Minoryx Therapeutics, S.L.
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Stanford University Medical Center | Palo Alto, California, United States | Recruiting |
| Neuro Medicine Hospital / UF Health | Gainesville, Florida, United States | Withdrawn |
| Kennedy Krieger Institute | Baltimore, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| University of Minnesota | Minneota, Minnesota, United States | Recruiting |
| Health University of Utah | Salt Lake City, Utah, United States | Withdrawn |
| Hospital Austral | Buenos Aires, Argentina | Recruiting |
| Federal University of Sao Paulo | São Paulo, Brazil | Recruiting |
| ICM La Pitie Salpetriere | Paris, France | Recruiting |
| Klinik und Poliklinik für Neurologie-Leipzig | Leipzig, Germany | Recruiting |
| Sir Ganga Ram Hospital | New Delhi, India | Recruiting |
| Hospital 12 de Octubre | Madrid, Spain | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05819866